No association was observed between familial breast cancer risk and CAM use.

No association was seen with sporadic or low-risk familial breast cancer.

The considerable heterogeneity in familial breast cancer means that different criteria for familiality can influence the result.

Each locus is believed to account for approximately 40% of cases of familial breast cancer.

The prevalence is increased in familial breast cancer and the variant seems to influence age at onset.

Analyses were adjusted for age, body mass index, height, parity, familial breast cancer, smoking and oral contraceptive use.

These results suggest that BRCA1 is not a major breast cancer susceptibility gene in Japanese familial breast cancer.

Palestinian women with young onset or familial breast cancer and their families would benefit from genetic analysis and counseling.

In an attempt to identify chromosomal regions harboring putative breast cancer genes we performed allelotyping in 82 familial breast carcinomas.

The familial patients from both cohorts were further divided into high- and low-risk familial breast cancer based on pedigree analysis.

Conclusion: The results of this study indicated that the common C975G variant may have an effect on familial breast cancer susceptibility.

It is now estimated that 28% of familial breast cancer risk is explained by common breast cancer susceptibility loci.

The preventive effect was particularly consistent in postmenopausal women and in those showing familial breast cancer (three or more affected patients).

Inherited pathogenic variants in genes that confer moderate to high risk of breast cancer may explain up to 50% of familial breast cancer.

Background: BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis.

To test this hypothesis, we genotyped 69 mtDNA variations in 156 unrelated European-American females with familial breast cancer and 260 age-matched European-American female controls.